Claris Lifesciences net falls by 28.6% in Q1

Consolidated EBITDA is at Rs 541 million Claris Lifesciences announced its un-audited financial results for the quarter ended March 31, 2013 at its recently held board meeting in Mumbai. The consolidated revenues for the quarter stood at Rs 1,822 ...

Claris Lifesciences has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2013, inter alia, have considered and approved the resignation tendered by Mr. Rajesh Kumar Modi as the Company Secretary and Compliance Officer of ...

Mumbai, May 10 : Claris Lifesciences Ltd., a leading sterile injectables pharmaceutical company, on Friday announced its un-audited financial results for the quarter ended 31st March, 2013 at its board meeting held at Mumbai.

Claris Lifesciences' promoter Aditya Sushil Kumar Handa has sold around 12 lakh shares amounting to 1.85% stake for over Rs 23 crore. Handa has offloaded 11,80,120 shares on an average price of about Rs 200 per share in the company through open ...

Kirit Kanjaria is appointed as company secretary and compliance officer of Claris Lifesciences with effect from 13 April 2013. Powered by Capital Market - Live News News Analyst Videos Archive New to site? Advantages » Important Links HDFC Group ...

Net profit of Claris Lifesciences declined 13.66% to Rs 1.39 crore in the quarter ended March 2013 as against Rs 1.61 crore during the previous quarter ended March 2012. Sales rose 1.97% to Rs 155.62 crore in the quarter ended March 2013 as against ...

Claris Lifesciences Limited (Claris) is a pharmaceutical company, based in India. It manufactures and distributes nutritional preparations, sterile injectables and hospital products. The company's products include anesthesia, nutrition, plasma ...

Claris Lifesciences Ltd. (CLAR) may be the next takeover target among Indian injectable-drug producers as a shortage of medicines in the U.S. prompts buyers to seek companies with approved manufacturing facilities. Claris could fetch more than ...